Your browser doesn't support javascript.
loading
Bone marrow-derived mesenchymal stem cells mitigate chronic colitis and enteric neuropathy via anti-inflammatory and anti-oxidative mechanisms.
Stavely, Rhian; Robinson, Ainsley M; Fraser, Sarah; Filippone, Rhiannon T; Stojanovska, Vanesa; Eri, Rajaraman; Apostolopoulos, Vasso; Sakkal, Samy; Nurgali, Kulmira.
Afiliação
  • Stavely R; Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  • Robinson AM; Department of Pediatric Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Fraser S; Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  • Filippone RT; Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  • Stojanovska V; Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  • Eri R; Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
  • Apostolopoulos V; The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
  • Sakkal S; School of Science, STEM College, RMIT University, Melbourne, VIC, Australia.
  • Nurgali K; Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
Sci Rep ; 14(1): 6649, 2024 03 20.
Article em En | MEDLINE | ID: mdl-38503815
ABSTRACT
Current treatments for inflammatory bowel disease (IBD) are often inadequate due to limited efficacy and toxicity, leading to surgical resection in refractory cases. IBD's broad and complex pathogenesis involving the immune system, enteric nervous system, microbiome, and oxidative stress requires more effective therapeutic strategies. In this study, we investigated the therapeutic potential of bone marrow-derived mesenchymal stem cell (BM-MSC) treatments in spontaneous chronic colitis using the Winnie mouse model which closely replicates the presentation and inflammatory profile of ulcerative colitis. The 14-day BM-MSC treatment regimen reduced the severity of colitis, leading to the attenuation of diarrheal symptoms and recovery in body mass. Morphological and histological abnormalities in the colon were also alleviated. Transcriptomic analysis demonstrated that BM-MSC treatment led to alterations in gene expression profiles primarily downregulating genes related to inflammation, including pro-inflammatory cytokines, chemokines and other biomarkers of inflammation. Further evaluation of immune cell populations using immunohistochemistry revealed a reduction in leukocyte infiltration upon BM-MSC treatment. Notably, enteric neuronal gene signatures were the most impacted by BM-MSC treatment, which correlated with the restoration of neuronal density in the myenteric ganglia. Moreover, BM-MSCs exhibited neuroprotective effects against oxidative stress-induced neuronal loss through antioxidant mechanisms, including the reduction of mitochondrial-derived superoxide and attenuation of oxidative stress-induced HMGB1 translocation, potentially relying on MSC-derived SOD1. These findings suggest that BM-MSCs hold promise as a therapeutic intervention to mitigate chronic colitis by exerting anti-inflammatory effects and protecting the enteric nervous system from oxidative stress-induced damage.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pseudo-Obstrução Intestinal / Doenças Inflamatórias Intestinais / Colite / Transplante de Células-Tronco Mesenquimais / Células-Tronco Mesenquimais Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pseudo-Obstrução Intestinal / Doenças Inflamatórias Intestinais / Colite / Transplante de Células-Tronco Mesenquimais / Células-Tronco Mesenquimais Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article